PT-141 for male ED: what the FDA says

PT-141 shows up constantly in online peptide-forum threads as a fix for erectile dysfunction in men. The FDA-approved medicine built on the same molecule, sold under the brand Vyleesi, treats something different: hypoactive sexual desire disorder (HSDD), a diagnosis of persistently low sexual desire that causes distress, in premenopausal women. The prescribing label is direct about the mismatch. It states that bremelanotide, PT-141's proper drug name, is ^[1], which contradicts the framing common in online peptide communities, where PT-141 gets discussed as a male performance aid.

What PT-141 actually is

Bremelanotide is a synthetic peptide, a short chain of amino acids, built as an analogue of alpha-MSH (alpha-melanocyte-stimulating hormone), a natural signal the body uses for skin pigmentation and several brain functions. The label describes it as a melanocortin receptor agonist, meaning it activates several receptor subtypes in that family, with its strongest action at MC1R and MC4R^[1]. Unlike drugs such as sildenafil, which act on blood vessels, bremelanotide is thought to act in the central nervous system. The label adds that the exact mechanism by which it improves HSDD is not established^[1].

The one FDA-approved use: HSDD in premenopausal women

The FDA approved Vyleesi, NDA 210557, in 2019 for premenopausal women with acquired, generalized HSDD: low sexual desire that is not explained by another medical or psychiatric condition, a relationship problem, or a medication side effect^[2][4]. The label specifies a 1.75 mg subcutaneous injection, self-administered with an autoinjector into the abdomen or thigh, at least 45 minutes before anticipated sexual activity, with a maximum of one dose per day and no more than eight doses per month^[1]. That dosing detail describes what the approved product's own instructions say. It is not a recommendation for how PT-141 obtained from any other source should be used.

The evidence behind that approval comes from RECONNECT, two identically designed phase 3 randomized, double-blind, placebo-controlled trials in roughly 1,200 premenopausal women with HSDD. Bremelanotide produced statistically significant improvements over placebo on measures of both desire and distress^[3]. The effect sizes were modest rather than dramatic, and the trials measured desire and distress in women. They say nothing about erectile function in men.

What this is not: a treatment for male erectile dysfunction

Grey-market vendors and forum threads frequently market PT-141 to men as an on-demand libido or erection aid, sometimes alongside or instead of a PDE5 inhibitor such as tadalafil. The FDA label directly contradicts that framing. Its limitations-of-use section states that bremelanotide is not indicated for men and is not indicated to enhance sexual performance in general^[1]. No FDA-approved product built on this molecule exists for male sexual dysfunction, and the agency has not evaluated any male-use dosing schedule for safety or effectiveness.

The clinical literature reflects the same gap. A 2026 commentary in the Journal of Clinical Psychopharmacology posed the question directly in its title, asking whether bremelanotide should even be considered for treating sexual arousal and desire disorders in men^[5]. A paper asking whether a use should be considered is not evidence that the use works or is safe. It is a sign the question remains open in the specialist literature, seven years after the approved product for women reached the market. Anyone weighing off-label PT-141 for male sexual function is relying on a far thinner evidence base than the one behind Vyleesi, and the current literature does not establish that off-label male use is either effective or safe.

The side effects the label lists

In the RECONNECT trials, nausea was the standout adverse event, reported by about 40% of women on bremelanotide^[1]. Flushing occurred in roughly 20%, injection-site reactions in about 13%, headache in about 11%, and vomiting in about 5%^[1]. The label also documents a transient rise in blood pressure, averaging 6 mmHg systolic and 3 mmHg diastolic, alongside a temporary drop in heart rate; both typically resolve within 12 hours^[1]. Those figures describe the approved dosing schedule in the population it was tested in. Off-label doses, off-label populations, and non-pharmaceutical-grade vials have not been through the same safety review, so none of these percentages can be assumed to carry over.

What we don't yet know

The RECONNECT programme did not enrol men or postmenopausal women, so there is no controlled trial data describing how bremelanotide performs, or what its side-effect profile looks like, in either group. An earlier intranasal version of the molecule was tested in men for erectile dysfunction in the early 2000s, but that programme did not lead to an approved product, and it is not the basis for anything sold today. Whether a sponsor pursues a dedicated male trial in the future is not something the current literature lets us predict.

If low desire or low libido is the actual concern, whether you are a man or a woman, the honest starting point is a conversation with a prescribing clinician who can weigh the approved options, including Vyleesi where it applies, against your medical history. The full PT-141 peptide page covers mechanism, safety and country-by-country access in more depth, the regulation section tracks where the drug is and is not lawfully available, and the US prescription pathway page covers what a valid US prescription actually requires.